[go: up one dir, main page]

DK1506301T3 - Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet - Google Patents

Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet

Info

Publication number
DK1506301T3
DK1506301T3 DK03735384T DK03735384T DK1506301T3 DK 1506301 T3 DK1506301 T3 DK 1506301T3 DK 03735384 T DK03735384 T DK 03735384T DK 03735384 T DK03735384 T DK 03735384T DK 1506301 T3 DK1506301 T3 DK 1506301T3
Authority
DK
Denmark
Prior art keywords
poxvirus
homological
expresses
genes
recombinant poxvirus
Prior art date
Application number
DK03735384T
Other languages
English (en)
Inventor
Paul Howley
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1506301T3 publication Critical patent/DK1506301T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03735384T 2002-05-16 2003-05-14 Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet DK1506301T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200753 2002-05-16
DKPA200200752 2002-05-16
PCT/EP2003/005047 WO2003097846A1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Publications (1)

Publication Number Publication Date
DK1506301T3 true DK1506301T3 (da) 2014-07-21

Family

ID=29551228

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03735384T DK1506301T3 (da) 2002-05-16 2003-05-14 Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet
DK03752741T DK1407033T3 (da) 2002-05-16 2003-05-14 Intergeniske områder som insertionssteder i genomet af Modified Vaccinia Virus Ankara (MVA)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03752741T DK1407033T3 (da) 2002-05-16 2003-05-14 Intergeniske områder som insertionssteder i genomet af Modified Vaccinia Virus Ankara (MVA)

Country Status (23)

Country Link
US (14) US7550147B2 (da)
EP (3) EP1407033B1 (da)
JP (4) JP4693092B2 (da)
KR (4) KR101005630B1 (da)
CN (6) CN100494388C (da)
AT (1) ATE315660T1 (da)
AU (4) AU2003236646B2 (da)
BR (2) BR0310051A (da)
CA (3) CA2481521C (da)
DE (1) DE60303218T2 (da)
DK (2) DK1506301T3 (da)
EA (3) EA020230B1 (da)
ES (1) ES2256776T3 (da)
HK (2) HK1076642A1 (da)
IL (4) IL164177A0 (da)
MX (2) MXPA04010713A (da)
NO (3) NO334273B1 (da)
NZ (2) NZ536501A (da)
PL (2) PL216760B1 (da)
PT (1) PT1407033E (da)
SI (1) SI1407033T1 (da)
UA (1) UA82479C2 (da)
WO (2) WO2003097846A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (da) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
KR20090057335A (ko) 2000-11-23 2009-06-04 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
DE60314823T3 (de) * 2002-04-19 2017-11-16 Bavarian Nordic A/S Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
BR0310051A (pt) * 2002-05-16 2005-02-15 Bavarian Nordic As Poxvìrus recombinante expressando genes homólogos inseridos no genoma poxviral
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
NZ538575A (en) * 2002-09-05 2007-03-30 Bavarian Nordic As Method for the amplification of a virus wherein primary avian cells are cultivated in a serum-free medium comprising growth factors and attachment factors
AU2004291024B2 (en) * 2003-02-20 2009-09-17 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Novel insertion sites in pox vectors
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
US7951576B2 (en) * 2004-11-05 2011-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for preparing cells and viruses
SI1855720T2 (sl) * 2005-02-23 2023-07-31 Bavarian Nordic A/S Uporaba modificiranega poksvirusa za hitro indukcijo imunosti proti poksvirusu ali drugim povzročiteljem infekcij
CN101535340B (zh) * 2006-05-19 2013-05-01 格利科菲公司 促红细胞生成素组合物
CN101563463B (zh) * 2006-08-25 2013-03-27 美国国有健康与人类服务部(马里兰州) 修饰的安卡拉（mva）痘苗病毒基因的基因组中保守基因之间的基因间位点
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
WO2008127307A2 (en) * 2006-11-09 2008-10-23 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
EP2118292B1 (en) * 2007-01-30 2011-08-03 Transgene SA Papillomavirus e2 polypeptide used for vaccination
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
CA2686772C (en) * 2007-05-15 2015-03-24 Transgene S.A. Vectors for multiple gene expression
JP2010528603A (ja) * 2007-05-30 2010-08-26 ワイス・エルエルシー ネコ抗原のアライグマポックスウイルス発現遺伝子
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
KR101648087B1 (ko) * 2007-10-18 2016-08-17 버베리안 노딕 에이/에스 전립선 암 치료를 위한 ｍｖａ의 용도
EP2303322A1 (en) * 2008-06-20 2011-04-06 Bavarian Nordic A/S Recombinant modified vaccinia virus measles vaccine
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
EP2352834B1 (en) * 2008-11-21 2016-12-21 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
SG178909A1 (en) 2009-10-08 2012-04-27 Bavarian Nordic As Generation of a broad t-cell response in humans against hiv
US9133480B2 (en) 2009-10-16 2015-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
CN103118709A (zh) * 2010-03-26 2013-05-22 新兴产品开发盖瑟斯堡有限公司 流感病毒基质2蛋白的胞外域、其表达系统和应用
NZ603620A (en) 2010-07-20 2015-01-30 Bavarian Nordic As Method for harvesting expression products
JP2013538577A (ja) * 2010-09-23 2013-10-17 バクスター・インターナショナル・インコーポレイテッド 組み換えウイルスベクターおよび黄熱病ウイルスに対する免疫反応を惹起するための方法
AU2011316164B2 (en) * 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
CN104093830A (zh) 2011-04-15 2014-10-08 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
IN2014DN10408A (da) 2012-06-05 2015-08-14 Univ Australian
EA031453B1 (ru) 2012-08-01 2019-01-31 Бавариан Нордик А/С Рекомбинантный модифицированный вирус осповакцины анкара (mva) и его применение
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
CA2888367A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
EP3685853A1 (en) * 2013-03-15 2020-07-29 Sementis Limited Immune modulation
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
CN107709554A (zh) * 2015-06-15 2018-02-16 巴法里安诺迪克有限公司 重组经修饰痘苗病毒安卡拉(mva)口蹄疫病毒(fmdv)疫苗
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
ES2944314T3 (es) 2016-01-08 2023-06-20 Geovax Inc Composiciones y procedimientos para generar una respuesta inmunitaria frente a un antígeno asociado a un tumor
ES2921605T3 (es) 2016-01-29 2022-08-30 Bavarian Nordic As Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
CN109862909A (zh) * 2016-08-19 2019-06-07 赛门蒂斯有限公司 病毒疫苗
US20200024610A1 (en) * 2016-09-30 2020-01-23 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
JP7272965B2 (ja) * 2017-06-15 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
JP2021523712A (ja) 2018-05-11 2021-09-09 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法
EP3850103A4 (en) 2018-09-15 2022-06-22 Memorial Sloan Kettering Cancer Center RECOMBINANT POXVIRUS FOR CANCER IMMUNOTHERAPY
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
BR112022009421A2 (pt) 2019-11-14 2022-10-25 Aelix Therapeutics S L Regimes de dosagem para vacinas
TW202203966A (zh) * 2020-03-31 2022-02-01 澳大利亞商賽門蒂斯公司 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
US20240033347A1 (en) 2022-07-08 2024-02-01 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
EP0597016A4 (en) 1991-07-26 1996-04-24 Virogenetics Corp Infectious bursal disease virus recombinant poxvirus vaccine.
DK0538496T3 (da) 1991-08-26 2004-02-23 Baxter Healthcare Sa Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
EP0561034B1 (en) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
ID19548A (id) * 1996-09-24 1998-07-23 Bavarian Nordic Res Inst As Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
WO2000073476A1 (en) * 1999-05-28 2000-12-07 Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
ES2249430T3 (es) * 2000-03-14 2006-04-01 Bavarian Nordic A/S Cepa alterada del virus ankara de la vacuna modificado (mva).
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
JP2004507249A (ja) * 2000-08-29 2004-03-11 ワイス・ホールディングズ・コーポレイション プラス鎖ｒｎａウイルスレプリコン粒子のパッケージング
KR20090057335A (ko) 2000-11-23 2009-06-04 버베리안 노딕 에이/에스 변형된 백시니아 앙카라 바이러스 변형체
BR0310051A (pt) 2002-05-16 2005-02-15 Bavarian Nordic As Poxvìrus recombinante expressando genes homólogos inseridos no genoma poxviral
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PL375740A1 (en) * 2002-11-25 2005-12-12 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ati promoters

Also Published As

Publication number Publication date
US20120039936A1 (en) 2012-02-16
US20120178157A1 (en) 2012-07-12
IL193087A (en) 2012-10-31
HK1076836A1 (en) 2006-01-27
IL164177A0 (en) 2005-12-18
KR101005630B1 (ko) 2011-01-05
IL193088A0 (en) 2009-02-11
DK1407033T3 (da) 2006-05-22
UA82479C2 (uk) 2008-04-25
AU2009200380C1 (en) 2010-03-11
US20120082696A1 (en) 2012-04-05
CN102719408A (zh) 2012-10-10
EA007811B1 (ru) 2007-02-27
CN1653183B (zh) 2012-07-25
WO2003097845A1 (en) 2003-11-27
JP2010259446A (ja) 2010-11-18
JP2011004755A (ja) 2011-01-13
PL218318B1 (pl) 2014-11-28
DE60303218D1 (de) 2006-04-06
EP2253709A1 (en) 2010-11-24
CA2481521A1 (en) 2003-11-27
CA2481521C (en) 2012-04-17
CA2481799A1 (en) 2003-11-27
NZ536501A (en) 2006-08-31
EA200900180A1 (ru) 2009-08-28
CN102199628A (zh) 2011-09-28
US20110053259A1 (en) 2011-03-03
NO20045480L (no) 2004-12-16
US7338662B2 (en) 2008-03-04
US20090311746A1 (en) 2009-12-17
CN102703393A (zh) 2012-10-03
EP1506301B1 (en) 2014-04-30
EA020230B1 (ru) 2014-09-30
EP1506301A1 (en) 2005-02-16
AU2009200380B2 (en) 2009-10-01
DE60303218T2 (de) 2006-09-14
NO334273B1 (no) 2014-01-27
ATE315660T1 (de) 2006-02-15
IL164172A0 (en) 2005-12-18
PL372088A1 (en) 2005-07-11
US20110053260A1 (en) 2011-03-03
IL193088A (en) 2015-02-26
NZ536502A (en) 2005-10-28
EP1407033B1 (en) 2006-01-11
AU2008255213A1 (en) 2009-01-08
WO2003097846A1 (en) 2003-11-27
JP4895505B2 (ja) 2012-03-14
CN1653184A (zh) 2005-08-10
CA2481799C (en) 2014-01-28
US7964374B2 (en) 2011-06-21
PL372093A1 (en) 2005-07-11
US8414900B2 (en) 2013-04-09
EA012160B1 (ru) 2009-08-28
US20130243813A1 (en) 2013-09-19
US8309326B2 (en) 2012-11-13
EA200401507A1 (ru) 2005-06-30
EP1407033A1 (en) 2004-04-14
PT1407033E (pt) 2006-05-31
IL193087A0 (en) 2009-02-11
CN1653183A (zh) 2005-08-10
US8288125B2 (en) 2012-10-16
US7550147B2 (en) 2009-06-23
US20100303856A1 (en) 2010-12-02
US20060165727A1 (en) 2006-07-27
BR0310051A (pt) 2005-02-15
US20100173388A1 (en) 2010-07-08
CN101831411A (zh) 2010-09-15
PL216760B1 (pl) 2014-05-30
NO336489B1 (no) 2015-09-07
US8741308B2 (en) 2014-06-03
KR20120002627A (ko) 2012-01-06
EP2253709B1 (en) 2018-04-11
KR20100110901A (ko) 2010-10-13
KR101041691B1 (ko) 2011-06-14
AU2003236646B2 (en) 2009-01-15
US8435543B2 (en) 2013-05-07
JP2005525822A (ja) 2005-09-02
US8034354B2 (en) 2011-10-11
AU2009200380A1 (en) 2009-02-19
AU2003242540A1 (en) 2003-12-02
CN100494388C (zh) 2009-06-03
JP4693092B2 (ja) 2011-06-01
CA2812019A1 (en) 2003-11-27
BRPI0311178B8 (pt) 2021-05-25
US20110250693A1 (en) 2011-10-13
HK1076642A1 (en) 2006-01-20
JP2005525823A (ja) 2005-09-02
EA200401506A1 (ru) 2005-04-28
NO20044940L (no) 2004-11-12
AU2008255213B2 (en) 2011-10-06
NO20111324A1 (no) 2011-09-29
AU2003236646A1 (en) 2003-12-02
BR0311178A (pt) 2005-03-29
KR20040108809A (ko) 2004-12-24
BRPI0311178B1 (pt) 2020-11-17
KR20040108798A (ko) 2004-12-24
MXPA04010713A (es) 2005-03-07
MXPA04011194A (es) 2005-02-14
KR101138067B1 (ko) 2012-04-24
ES2256776T3 (es) 2006-07-16
US20120135501A1 (en) 2012-05-31
US20110244574A1 (en) 2011-10-06
JP5777199B2 (ja) 2015-09-09
SI1407033T1 (sl) 2006-06-30
US20050244428A1 (en) 2005-11-03
US9109233B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
DK1506301T3 (da) Rekombinant poxvirus, der udtrykker homologe gener, der er indsat i poxvirusgenomet
MX2021010273A (es) Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral.
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
DE59510466D1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE60229962D1 (de) Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
DE69533102D1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
EP0815233A4 (en) NEW CYTOKININE FROM BIRDS AND CODING GENETIC SEQUENCES THEREFOR
KR20220107741A (ko) Gm-csf의 분비를 위한 유전자 구조물 및 이에 의해 형질전환된 항암 재조합 균주
KR100791996B1 (ko) 미엘린 염기성 폴리펩타이드를 분비하는 형질전환 미생물을함유하는 자가면역질환 치료용 조성물
WO2007031574A3 (en) Therapeutic use of outer shigella protein f (os pf)
AP2003002944A0 (en) Method to generate non virulent microorganisms from pathogenic ones through permanent genetic modification of their biological membrane for vaccine production.
AR046937A1 (es) Proteina nmb0928 y su uso en formulaciones farmaceuticas
Hurst The Medea Gene
Stram et al. Recombinant vaccines against IBDV
Rappuoli Annual Congress of the British Society for Immunology, 6-9 December 2005, Harrogate, UK. Abstracts
NO20063020L (no) Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer
DK200201813A (da) Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper